E70.81 ICD-10-CM Code: Aromatic L-amino acid decarboxylase deficiency
E70.81 is not a CMS-HCC payment code. MEAT criteria · RAF calculator · free HCC coding tools
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Endocrine, nutritional and metabolic diseases (E00-E89) / Metabolic disorders (E70-E88)
E70.81
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceAromatic L-amino acid decarboxylase deficiency
A rare genetic disorder where the enzyme aromatic L-amino acid decarboxylase is deficient, affecting the production of important neurotransmitters like dopamine and serotonin.
Buddy Insight
Aromatic L-amino acid decarboxylase deficiency is a rare, severe neurometabolic disorder that impairs the synthesis of dopamine, serotonin, epinephrine, and norepinephrine.
CMS-HCC V28
N/A—
Not mapped
CMS-HCC V24
MappedHCC 23
RAF 0.194
ACA/HHS
MappedHCC 28
Varies by metal level
ESRD/PACE
MappedHCC 23
RAF 0.036
RXHCC
MappedHCC 43
RAF 0.063
Code Book Path
Inclusion Terms
Official- AADC deficiency
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for E70.81 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for E70.81 in this effective period.
Excludes 1
OfficialICD-10-CM does not list Excludes 1 notes for E70.81 in this effective period.
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for E70.81 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for E70.81 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for E70.81 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is E70.81 an HCC code?
Yes. E70.81 maps to Other Significant Endocrine and Metabolic Disorders under the V24 model but is not retained in V28.
- Code
- E70.81
- Description
- Aromatic L-amino acid decarboxylase deficiency
- HCC (V28)
- No CMS-HCC V28 mapping
- RAF
- —
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
Each model's RAF is its CMS base weight for that model's standard population, so weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
Work E70.81 in the Code Book — tabular path, V28 RAF, and MEAT checklist →
MEAT Criteria for E70.81
For E70.81 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed E70.81 during that encounter, not just copy-forwarded from a problem list.
Coder workflow notes
Get the V28 RAF + MEAT cheat sheet
One printable page: confirm a code's V28 HCC status, its RAF weight, and the MEAT your note needs to make it stick. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
E70.81 is the ICD-10-CM diagnosis code for aromatic l-amino acid decarboxylase deficiency. A rare genetic disorder where the enzyme aromatic L-amino acid decarboxylase is deficient, affecting the production of important neurotransmitters like dopamine and serotonin. E70.81 sits in the ICD-10-CM chapter for endocrine, nutritional and metabolic diseases (e00-e89), within the section covering metabolic disorders (e70-e88).
Under the older CMS-HCC V24 model, E70.81 maps to Other Significant Endocrine and Metabolic Disorders (HCC 23) with a community, non-dual, aged base RAF weight of 0.194. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
This is a specific neurometabolic disorder; document associated neurological symptoms such as developmental delay, movement disorders, or autonomic dysfunction. Because E70.81 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for E70.81 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •This is a specific neurometabolic disorder; document associated neurological symptoms such as developmental delay, movement disorders, or autonomic dysfunction
- •Often presents in infancy with severe neurological manifestations; ensure comprehensive documentation of clinical presentation
Clinical Significance
Aromatic L-amino acid decarboxylase deficiency is a rare, severe neurometabolic disorder that impairs the synthesis of dopamine, serotonin, epinephrine, and norepinephrine. Affected infants present with severe developmental delay, oculogyric crises, dystonia, ptosis, autonomic dysfunction (temperature instability, excessive sweating, nasal congestion), and hypotonia. Gene therapy (eladocagene exuparvovec) has recently become available as a treatment option.
Documentation Requirements
- ✓Documentation must include confirmed diagnosis through cerebrospinal fluid neurotransmitter analysis showing low dopamine and serotonin metabolites with elevated L-dopa and 5-hydroxytryptophan, enzyme activity assay, or genetic testing of the DDC gene.
- ✓The severity of neurological manifestations, current medication regimen (dopamine agonists, monoamine oxidase inhibitors, pyridoxine), and functional status should be detailed.
- ✓If gene therapy has been administered, document the treatment and response.
Commonly Confused Codes
- •E70.89 (Other disorders of aromatic amino-acid metabolism) is less specific.
- •G24.x (Dystonia) codes the movement disorder but not the metabolic cause.
- •G71.x (Primary disorders of muscles) may be confused clinically in hypotonic infants.
- •E70.9 (Disorder of aromatic amino-acid metabolism, unspecified) should not be used when this specific diagnosis is confirmed.
- •G93.89 (Other specified disorders of brain) may be used for neurological complications.